This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. ##STR00001##

Re(V) alkylidyne-based catalytic systems for alkyne metathesis reactions capable of effecting alkyne metathesis, such as homo- and cross-metathesis of alkynes or diynes, ring closing metathesis and ring-opening metathesis, at room temperature to moderate temperatures. The catalysts are stable to air and moisture and tolerate a variety of functional groups in substrates and can be readily prepared on a large scale, and thus are practical catalytic systems of Re(V) alkylidynes.

Re(V) alkylidyne-based catalytic systems for alkyne metathesis reactions capable of effecting alkyne metathesis, such as homo- and cross-metathesis of alkynes or diynes, ring closing metathesis and ring-opening metathesis, at room temperature to moderate temperatures. The catalysts are stable to air and moisture and tolerate a variety of functional groups in substrates and can be readily prepared on a large scale, and thus are practical catalytic systems of Re(V) alkylidynes.

The invention is in the field of fragrances and relates to novel oxa-macrocyclic fragrance compounds according to general formula (I) with a musk-based note and improved biological degradability and further with improved chemical stabilities. The invention also relates to methods for preparing these compounds. Furthermore, the present invention also relates to fragrance compositions comprising one or more of the inventive compounds. Moreover, the invention relates to the use of these compounds or fragrance compositions as an odorant or for improving the fixation of a fragrance compound or a fragrance composition as well as for the preparation of a perfumed product. In addition, the present invention thus also refers to the use of said compounds or compositions for the preparation of a perfumed products as well as perfumed products as such.

The invention is in the field of fragrances and relates to novel oxa-macrocyclic fragrance compounds according to general formula (I) with a musk-based note and improved biological degradability and further with improved chemical stabilities. The invention also relates to methods for preparing these compounds. Furthermore, the present invention also relates to fragrance compositions comprising one or more of the inventive compounds. Moreover, the invention relates to the use of these compounds or fragrance compositions as an odorant or for improving the fixation of a fragrance compound or a fragrance composition as well as for the preparation of a perfumed product. In addition, the present invention thus also refers to the use of said compounds or compositions for the preparation of a perfumed products as well as perfumed products as such.

Chemiluminescent compositions, methods, assays and kits for oxidative enzymes are described. Further disclosed are dioxetane compounds of the form:

##STR00001##

where R can independently be any branched alkyl or cycloalkyl group which provides stabilization for the dioxetane or where both R groups together form a cycloalkyl or polycycloalkyl moiety spiro bound to the dioxetane ring, wherein each R group or the spiro bound moiety can be unsubstituted or substituted with one or more electron-withdrawing groups or electron donating groups, or groups providing preferential oxidative isozyme substrate recognition, and wherein R.sub.1 is an aryl group, or an alkyl group of 1-20 carbon atoms, which can be optionally substituted with 1 or more halogen atoms, and wherein T is an aryl or heteroaryl ring capable of emitting light upon enzyme activated decomposition of the dioxetane I.

Kits, methods and assays are also disclosed that comprise the dioxetane compounds.

The application relates to macrocyclic compounds and related polymers, as well as to processes for synthesizing them, e.g., using olefins as starting material.

The application relates to macrocyclic compounds and related polymers, as well as to processes for synthesizing them, e.g., using olefins as starting material.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.